Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.

Kingsbury, Daniel J

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. [electronic resource] - Clinical rheumatology 2014 - 1433-41 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1434-9949

10.1007/s10067-014-2498-1 doi


Adalimumab
Antibodies, Monoclonal, Humanized--adverse effects
Antirheumatic Agents--adverse effects
Arthritis, Juvenile--blood
Biomarkers--blood
C-Reactive Protein--metabolism
Child, Preschool
Dose-Response Relationship, Drug
Drug Therapy, Combination
Europe
Female
Humans
International Cooperation
Male
Methotrexate--therapeutic use
Treatment Outcome
United States